Please read this page before participating in this activity. At the bottom of the page, select “I have read these instructions and understand them,” and then click “Begin Activity.”
Overview
Archive, CME credit no longer available
Release Date: May 14, 2007
Expiration Date: May 14, 2008
This activity consists of audio and visual recording of 8 live presentations. To receive CME credit, please read the overview and follow the link to the presentation.
To view presentation, the learner should click on a presentation title. The Webcast will open in a separate window. The learner may view as many presentations in this activity as he/she chooses. Learner agrees that slides are for webcast viewing only. He or she will not copy, alter, or change these Webcast presentations in any way.
Once 1 or more presentations have been reviewed, learners may link to the CME evaluation from a link at the top of the main index of presentations. This is required for credit. Instructions for the evaluation are found on that page.
Needs and Objectives
Upon completion of this activity, learners will be able to:
- Design antiretroviral strategies that consider current data on:
- Initiating therapy, early failure, and complicated failure
- Interpreting of resistance test results
- The status of investigational antiretroviral drugs
- Metabolic toxicities of HIV and its therapies, including renal disease
- Formulate appropriate management strategies for HIV coinfection with hepatitis B virus
- Describe the incidence, diagnosis, and management of human papillomavirus in HIV-infected patients, including the role of the vaccine
Intended Audience
This online CME activity is designed for physicians who are actively involved in HIV/AIDS care. Specifically, these activities have been designed for physicians who:
- Have a solid, working knowledge of HIV disease management
- Provide comprehensive or specialty care for at least 10 patients with HIV/AIDS or are involved in HIV/AIDS clinical trials or investigations
- Have completed at least 10 hours of CME in the area of HIV/AIDS medicine in the past 2 years
This activity is also relevant to nurse practitioners, physician assistants, nurses, and other health professionals who provide care to people with HIV disease.
Course Faculty
Chairs
Michael S. Saag, MD
Course Chair
Member, Board of Directors
International AIDS Society–USA
Professor of Medicine
Director, Center for AIDS Research
The University of Alabama at Birmingham
Birmingham, Alabama
Jeffrey L. Lennox, MD
Course Vice-Chair
Professor of Medicine
Emory University School of Medicine
Medical Director
Infectious Disease Program
Grady Health System
Atlanta, Georgia
Speakers
Ruth E. Berggren, MD
Associate Professor of Clinical Medicine
The University of Texas Health Science Center at San Antonio
San Antonio, Texas
Carlos del Rio, MD
Member, Board of Directors
International AIDS Society–USA
Professor of Medicine
Emory University School of Medicine
Chief of Medical Services
Grady Memorial Hospital
Atlanta, Georgia
Colleen M. Hadigan, MD, MPH
Staff Clinician
National Institute of Allergy and
Infectious Diseases
National Institutes of Health
Bethesda, Maryland
Richard H. Haubrich, MD
Professor of Medicine
Division of Infectious Diseases
University of California San Diego
San Diego, California
W. Christopher Mathews, MD, MPH
Professor of Clinical Medicine
Director, Owen Clinic
University of California San Diego
San Diego, California
Lynda A. Szczech, MD
Assistant Professor
Duke University Medical Center
Durham, North Carolina
Panelists
David Rimland, MD
Chief of Infectious Diseases
Veterans Affairs Medical Center
Decatur, Georgia
Melanie A. Thompson, MD
Principal Investigator
AIDS Research Consortium of Atlanta
Atlanta, Georgia
Disclosure of Financial Affiliations
In the interest of maintaining the independence of its continuing medical education (CME) activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education, the International AIDS Society-USA requires all persons with control of content (ie; faculty, IAS-USA Board members, and program staff) to disclose any financial relationships that they (or their spouses or partners) have had with commercial companies within the past 12 months of the date of this Web-based CME conference. Any conflicts of interest of those parties are resolved prior to the education activity being delivered.
IAS-USA Board of Directors
Constance A. Benson, MD
Dr Benson received research support from or served as a consultant to Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck, and Pfizer. She had stock options for Monogram Biosciences and Vertex. (Updated 03/21/07)
Judith S. Currier, MD
Dr Currier received grants and research support from and served as a consultant to Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, and Tibotec. (Updated 03/12/07)
Carlos del Rio, MD
Dr del Rio received grants and research support from GlaxoSmithKline, Merck, and Pfizer. He served as a consultant or was on the speakers’ bureau of Abbott, Merck, and Roche. (Updated 10/09/06)
Joel E. Gallant, MD, MPH
Dr Gallant received grants and research support from Gilead, GlaxoSmithKline, Merck, Pfizer, Roche, and Tibotec, and honoraria from Abbott, Gilead, GlaxoSmithKline, Monogram Biosciences, and Tibotec. He served as a scientific advisor or consultant to Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Koronis, Merck, Monogram Sciences, Panacos, Pfizer, Schering Plough, Tibotec, and Vertex. (Updated 10/09/07)
Roy M. Gulick, MD, MPH
Dr Gulick received research grants from Gilead, Merck, Panacos, Pfizer, Schering, and Tibotec. He served as a scientific advisor or consultant to Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Monogram Biosciences, Pfizer, Roche-Trimeris, Schering, Tibotec, and Virco. (Updated 03/05/07)
Donna M. Jacobsen
Ms Jacobsen had no relevant financial affiliations to disclose. (Updated 03/22/07)
Douglas D. Richman, MD
Dr Richman served as a consultant to Achillion, Anadys, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Idinex, Merck, Monogram, Pfizer, Roche, and Tibotec. (Updated 10/09/06)
Michael S. Saag, MD
Dr Saag received grants and research support from Achillion Pharmaceuticals, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck, Panacos, Pfizer, Progenics, Roche, Serono, Tibotec, Trimeris, and Vertex. He served as a scientific advisor to Achillion, Avexa, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Monogram Biosciences, Panacos, Pfizer, Progenics, Roche, Tanox, Tibotec/Virco, Trimeris, and Vertex. (Updated 03/22/07)
Robert T. Schooley, MD
Dr Schooley received and research support and honoraria from or served as a consultant to Abbott, Anadys, Anormed, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Monogram Biosciences, Pfizer, Roche, Schering-Plough, Tanox, Tibotec and Vertex. (05/16/07)
Paul A. Volberding, MD
Dr Volberding served on the advisory boards for Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Pfizer, and Schering, and was on the endpoint adjudication committee of Schering. He received honoraria for speaking from Bristol-Myers Squibb, Gilead, and Vertex. He had stock options for Immune Response Corporation. (Updated 01/22/07)
Course Faculty and Staff
Below are the disclosures of financial relationships of the faculty and program staff of this Web-based CME conference.
Dr Berggren’s spouse or partner owned stock in Vertex.
Dr del Rio received grants and research support from GlaxoSmithKline, Merck, and Pfizer. He served as a consultant or was on the speakers’ bureau of Abbott, Merck, and Roche.
Dr Hadigan received grants and research support from or served as a consultant to Bristol-Myers Squibb and Gilead.
Dr Haubrich received grants and research support from Abbott, Gilead, and GlaxoSmithKline. He served as a scientific advisor to Abbott, Monogram, Roche, and Trimeris. He received honoraria from Abbott, Boehringer Ingelheim, Gilead, Monogram Biosciences, Roche, and Trimeris.
Dr Lennox received grants and research support or honoraria from Abbott, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck, Pfizer, Roche, Schering, and Tibotec. He served a consultant to or was on the speakers’ bureau of Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Pfizer, Roche, and Tibotec.
Dr Mathews had no relevant financial affiliations to disclose.
Dr Rimland had no relevant financial affiliations to disclose.
Dr Saag received grants and research support from Achillion Pharmaceuticals, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck, Panacos, Pfizer, Progenics, Roche, Serono, Tibotec, Trimeris, and Vertex. He served as a scientific advisor to Achillion, Avexa, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Monogram Biosciences, Panacos, Pfizer, Progenics, Roche, Tanox, Tibotec/Virco, Trimeris, and Vertex.
Dr Szczech served as a consultant to or was on the speakers’ bureau of Abbott, Gilead, and GlaxoSmithKline.
Dr Thompson served as a consultant or scientific advisor to Abbott, Agouron/Pfizer, GlaxoSmithKlilne, Gilead, Panacos, Serono, and Tibotec. She received honoraria from Abbott, Agouron/Pfizer, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Gilead, Roche, Serono, Tibotec, and Trimeris.
IAS–USA CME Staff
Ms Jacobsen has no relevant financial affiliations to disclose.
Ms Wilson has no relevant financial affiliations to disclose.
Grant Support
This Webcast activity is sponsored by the International AIDS Society–USA and funded by the International AIDS Society–USA.
Funding for the live activity, upon which this activity was based came from the following commercial companies:
Substantial Grants from:
Bristol-Myers Squibb
Tibotec Therapeutics
Abbott Laboratories
Gilead Sciences
Pfizer Global Pharmaceuticals
Roche Pharmaceuticals
Generous Grants from:
GlaxoSmithKline
Additional grant support for this course:
Merck and Co., Inc.
Discussion of Investigational or Unapproved Usage
This activity presents an update on new research that may involve the use of investigational or unapproved drugs and therapies. Participants should consult the product information and other resources for comprehensive information on drugs and therapies discussed in the cases. The views and opinions expressed herein are those of the faculty and do not necessarily represent the opinions or recommendations of the International AIDS Society–USA.
Contact Information
If you have any questions about this Web-based CME conference activity, please contact the International AIDS Society–USA:
International AIDS Society–USA
425 California Street
Suite 1450
San Francisco, CA 94104-2120
Telephone: 415-544-9400
Fax: 415-544-9401
E-mail: registration2007@iasusa.org
